STOCK TITAN
  1. Home
  2. News
  3. CYTK

Cytokinetics Inc - CYTK STOCK NEWS

Welcome to our dedicated news page for Cytokinetics (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytokinetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytokinetics's position in the market.

News
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) will report fourth-quarter results on February 27, 2024, followed by a conference call to discuss operational and financial outcomes. The live webcast and telephonic access details are provided for interested participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
earnings
-
News
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) President and CEO, Robert I. Blum, will participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The live webcast can be accessed on the company's website, with a replay available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
conferences
-
News
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the recipients of its sixth annual Communications Grant Program, awarding a total of $100,000 to five patient advocacy organizations. The grants, amounting to $20,000 each, are intended to support increased capacity in communications, awareness building, and community engagement for the hypertrophic cardiomyopathy (HCM), heart failure, and amyotrophic lateral sclerosis (ALS) communities. The grants will be utilized for projects aimed at increasing access to resources, expanding organizational reach, and launching educational programs. The recipients include the ALS Therapy Development Institute, the Hypertrophic Cardiomyopathy Association, and three other patient advocacy organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
News
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function, and fibrosis related to treatment with aficamten in patients with hypertrophic cardiomyopathy (HCM). The data showed that treatment with aficamten for 48 weeks resulted in statistically significant improvements in measures of cardiac structure and function, including left ventricular mass index, maximum left ventricular septal wall thickness, left atrial volume, and mitral regurgitant volume and fraction. Additionally, treatment with aficamten stabilized interstitial and replacement myocardial fibrosis, with no increase in the fibrosis mass. These findings suggest potential disease-modifying effects of aficamten in patients with obstructive HCM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
-
News
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) will present the Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy at CMR 2024 in London, UK from January 25-27, 2024. The presentation will be conducted by Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University, during the Rapid Fire session on January 25, 2024, at 2:55 – 3:00 PM GMT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) granted 6,150 stock options to three new employees as a material inducement to their employment. The options have an exercise price of $83.49 per share, vest over 4 years, and have a 10-year term. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
News
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) to present at 42nd Annual J.P. Morgan Healthcare Conference. Robert I. Blum, President and CEO, to present on January 8, 2024. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences
-
News
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) announced positive topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The results show that treatment with aficamten significantly improved exercise capacity compared to placebo, with a statistically significant increase in peak oxygen uptake. The treatment effect was consistent across all prespecified subgroups. Statistically significant and clinically meaningful improvements were also observed in all 10 prespecified secondary endpoints. Aficamten was well-tolerated with an adverse event profile comparable to placebo. Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be <50% in a small percentage of patients on aficamten, but there were no instances of worsening heart failure or treatment interruptions due to low LVEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.54%
Tags
clinical trial
-
News
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) to discuss topline results from pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.54%
Tags
conferences clinical trial
News
Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the discontinuation of the clinical trial for reldesemtiv, a potential treatment for ALS, due to lack of efficacy. The trial, COURAGE-ALS, did not show any effect on the primary endpoint of change from baseline in ALSFRS-R or key secondary endpoints. The development of reldesemtiv has been terminated, disappointing results for the company after more than a decade of pursuit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
none
Stock CYTK logo
Cytokinetics Inc

Nasdaq:CYTK

CYTK Rankings

#985 Ranked by Market Cap
#3725 Ranked by Stock Gains
N/A Ranked by Dividends

CYTK Stock Data

7.48B
102.33M
0.57%
112.63%
12.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About CYTK

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.